Innocent Valea
| Current Job | Research scientist |
| Personal Statement | PharmD by background, I completed a MSc and a PhD degree in health biology and medical sciences, respectively. As a Medical scientist, specialized in epidemiology and clinical research, I actively contributes to the design and implementation of research projects, including epidemiological studies and clinical trials on malaria and other infectious diseases. I was involved in the setup and development of the ClinicalResearch Unit of Nanoro (CRUN) as one of the site leaders. Having completed an auditor/lead auditor ISO certified training for quality management systems, I supervise the quality management system of CRUN at the position of deputy head and QA manager. With more than fifteen years’ experience in clinical research and a track record of over 40 projects successfully implemented, I also share my field experiences through lectures on clinical research and surveillance, monitoring and evaluation of health interventions and particularly malaria control programs. I am actively involved in several health sciences research projects covering capacity building, community based interventions and product development including drug and vaccines with regular contacts with the policy makers and program implementers at Ministry of health level. With more than ten-year’s experience as deputy head of CRUN, and two-year’s experience as Executive director of the National Centre for Research and Training on Malaria, Ministry of Health, Burkina Faso, I was able to develop a strong expertise in implementing international research standards, and good skills in networking and team building. I have authored/co-authored more than 70 scientific papers in peer-review journals, with a specific interest on malaria epidemiology, drug efficacy, operational research, and community based interventions. |
| Education | 1.PhD in Medical Sciences, 2013, Antwerp University Belgium 2.Trainer certificate in Good Clinical Practices (ICH-GCP), 2012, EDCTP/ITM Antwerp, Belgium 3.Auditor/Lead Auditor for Quality Management Systems, 2012, Moody International, France 4.Monitoring/evaluation – Malaria control programs, 2011, Measure/USAID/CRSN 5.Clinical research and evidence based medicine, 2009, Institute of Tropical Medicine, Antwerp, Belgium 6.Strategic management, 2008, Strathmore Business School, Kenya 7.Master in International Health (health biology), 2005, Victor Segalen university, Bordeaux 2, France 8.University diploma in malaria control, 2003, University La Timone, Marseille, France 9.Pharm D, 2002, University of Ouagadougou, Burkina Faso |
| Experiences | 1. Executive Director, National Centre for Research and Training on Malaria (CNRFP), Ministry of Health, Burkina Faso, Jul 2016- Jan 2018. 2. Deputy Head/Quality assurance manager, Clinical Research Unit of Nanoro (IRSS/CRUN), Burkina Faso, 2009-2016 3.Associate researcher, Department of Clinical Research, Centre Muraz, Bobo-Dioulasso-Burkina Faso, 2005-2016 4. Network Manager, West African Network 2 for monitoring antimalarial treatments (WANMAT2), Bobo-Dioulasso – Burkina Faso, 2005-2007 5. Pharmacist, Vaccinology and Epidemiology unit, Centre Muraz, Bobo-Dioulasso – Burkina Faso, 2003- 2005 |
 |
PubMed Link |
| Research Grants | CHIMIO study: 2021-2022 Evaluation de trois combinaisons à base d’artemisinine pour le traitement du paludisme non compliqué chez les enfants au Burkina Faso SINFOFO Trial: Phase II multicenter clinical trial of a Ferroquine + ZY19489 (MMV253) short regimen for the treatment of malaria ARES study: 2017- 2021 : Amélioration de la santé maternelle et infantile par la prévention des co-infections paludisme et maladies sexuellement transmises chez les femmes enceintes au Burkina Faso (ARES) ACHIV-CT14B: 2016 – 2021 : A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of 1 or 2 doses of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents (ACHIV-Ebola) GSK Biologicals, Belgium : 2011 – 2017 : Malaria 63 Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine, when administered as primary vaccination with rotavirus vaccine and pneumococcal conjugate vaccine at 6, 10 and 14 weeks of age, to infants living in a malaria-endemic region in Africa |
 |
ORCID Link |
 |
Publons Link |
 |
ResearchGate Link |
 |
LinkedIn Link |
Click to rate!
[Total: 0 Average: 0]
